Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Total Non-current Liabilities
All obligations due after more than one year.
Forte Biosciences, Inc.NASDAQ: FBRX
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities remains negative
Q1 FY2026 total non-current liabilities was $1.48M, compared with $0 a year earlier.
Context
- Total non-current liabilities amounted to 2.2% of total assets at the end of Q1 FY2026, up 2.2 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.04M USD
- Year-over-year change
- —
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.04M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Non-current Liabilities vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Total non-current liabilities amounts to 2.2% of total assets for FBRX, versus a peer median of 11.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $188.57M USD | -7.5% | -26.1% | 78.6% | |
| Mar 2026 | $74.52M USD | -9.2% | -11.1% | 26.2% | |
| Mar 2026 | $68.01M USD | -6.9% | -4.0% | 18.3% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $16.9M USD | +115.9% | +32.8% | 74.5% |
| Mar 2026 | $13.35M USD | -11.9% | -10.0% | 8.5% | |
| Mar 2026 | CHF 10.38M CHF | +163.4% | +3.0% | 11.9% | |
| Mar 2026 | $1.48M USD | — | — | 2.2% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $404.99K USD | -2.8% | -32.3% | 4.5% |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | -63.2% | 0.0% | |
| Peer median (excluding FBRX) | — | -7.5% | -10.6% | 11.9% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.